TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22040450
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg oral midazolam
Study: 20159176
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (Group A) delivering 20 mcg of EE and 150 mcg of norelgestromin
Study: 20159176
Drug: Contraceptive vaginal
Normalized name: VCF 4% Contraceptive Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive vaginal ring (Group B) releasing 15 mcg of EE and 120 mcg of etonorgestrel
Study: 18470901
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide pneumococcal vaccine (PPV) alone
Study: 20720342
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) training
Study: 16174275
Drug: Systemic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic amoxicillin and metronidazole (500 mg each, three times a day for 7 days)
Study: 10094939
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) therapy for 4 years
Study: 26948070
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose free fatty acid (FFA) suppositories
Study: 26948070
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose free fatty acid (FFA) suppositories
Study: 24831577
Drug: High-dose rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rosuvastatin
Study: 15227611
Drug: Daptomycin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (4 mg/kg intravenously every 24 h for 7‐14 days)
Study: 15227611
Drug: Conventional antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotics (penicillinase‐resistant penicillins or vancomycin)
Study: 15227611
Drug: Daptomycin and
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daptomycin and Conventional antibiotics
Study: 11092405
Drug: Nitroglycerin (NG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NG) ointment applied to the skin once a day for 1 year
Study: 11092405
Drug: Estrogen replacement
Normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen replacement therapy (Premarin)
Study: 9344303
Drug: Computer-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based treatment system
Study: 3103338
Drug: EHDP 10
Normalized name: EHDP
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EHDP 10 mg/kg daily for 3 months
Study: 3103338
Drug: EHDP 5
Normalized name: EHDP
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EHDP 5 mg/kg daily for 6 months
Study: 3103338
Drug: EHDP 5
Normalized name: EHDP
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EHDP 5 mg/kg and 10 mg/kg
Study: 3103338
Drug: Calcitonin (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin (standard therapy)
Study: 20842947
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone (5 g/L/d)
Study: 20842947
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone with other therapy
Study: 20842947
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone with other therapy
Study: 20842947
Drug: Intratympanic methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic methylprednisolone without other therapy
Study: 9874127
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon-alpha (2 x 10(6) IU/g) in hydrophilic gel (hydroxyethylcellulose, 1%)
Study: 2237968
Drug: Active antithrombotic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antithrombotic therapy (warfarin or aspirin)
Study: 104897
Drug: biguanide administration
Normalized name: biguanide
DrugBank: Biguanide (DB13100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: biguanide administration
Study: 22520250
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg daily
Study: 25850030
Drug: Clopidogrel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (150 mg daily for 6 days then 75 mg daily)
Study: 22407658
Drug: β‐blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐blocker
Study: 22407658
Drug: behavioral migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: behavioral migraine management + β‐blocker
Study: 12050836
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg to 5 mg of intravenous morphine
Study: 111288
Drug: 0.5 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg, 1.5 mg, or 2.5 mg physostigmine i.v.
Study: 111288
Drug: Oral choline
Normalized name: choline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral choline chloride (8 g/day for 3 weeks or 16 g/day for 1 week)
Study: 6360198
Drug: Heparin (10000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (10000 i.u. subcutaneously twice daily) throughout pregnancy and labour
Study: 30667494
Drug: Web-based symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based symptom monitoring during chemotherapy
Study: 26708301
Drug: Drospirenone-only pill
Normalized name: drospirenone Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone-only pill (4 mg) with scheduled 24-h delays in tablet intake
Study: 26708301
Drug: Regular intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular intake of drospirenone-only pill
Study: 21797805
Drug: Etanercept plus
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept plus nbUVB (50 mg once a week + nbUVB three times weekly for 4 weeks)
Study: 21797805
Drug: Etanercept monotherapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept monotherapy (50 mg once a week)
Study: 21797805
Drug: Etanercept monotherapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept monotherapy (for patients with high adherence)
Study: 20864251
Drug: Intravesical botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical botulinum toxin type A (BoNTA) injection
Study: 20864251
Drug: Intravesical botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical botulinum toxin A (BoNTA) injection
Study: 15781750
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg IV
Study: 15781750
Drug: Fondaparinux 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 5.0 mg IV
Study: 2651663
Drug: No local
Approvals — FDA: no, EMA: no, PMDA: no
Description: No local antibiotic therapy (group B)
Study: 31937049
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine treatment including smoking quitting persuasion, vaccination, oxygen therapy and standardized medication)
Study: 26506852
Drug: Placebo (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50 mg of cellulose)
Study: 21439850
Drug: l-carnitine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-carnitine (1,000 mg/day for 12 weeks)
Study: 10934081
Drug: rPAF‐AH (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPAF‐AH (1 mg/kg)
Study: 19231487
Drug: rPAF‐AH (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rPAF‐AH (5 mg/kg)
Study: 14871165
Drug: Wait-and-see policy
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wait-and-see policy vs Corticosteroid injections
Study: 14871165
Drug: Physiotherapy vs
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapy vs Corticosteroid injections
Study: 30623563
Drug: Lixisenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (10 μg subcutaneously)
Study: 28700489
Drug: Dexmedetomidine (a
Normalized name: dexmedetomidine (as hydrochloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (a bolus dose of 0.5 μg/kg and then an infusion of 0.5 μg/kg/h)
Study: 16384561
Drug: Simvastatin plus
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin plus L-carnitine (2g/day)
Study: 20529243
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day)
Study: 1358132
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of nilvadipine
Study: 1358132
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of nilvadipine
Study: 22361711
Drug: Pozarevac area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pozarevac area with mean Mg level of 42 mg L(‐1)
Study: 22361711
Drug: Grocka area
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grocka area with mean Mg level of 11 mg L(‐1)
Study: 20860504
Drug: Fondaparinux, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux, 2.5 mg once daily for 45 days
Study: 17971707
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (3 g twice daily)
Study: 3314972
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser treatment with contiguous or overlapping laser spots
Study: 3314972
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser treatment at twice the minimum blanching power
Study: 3314972
Drug: Neodymium (Nd)
Normalized name: Neodymium
DrugBank: Neodymium (DB15318)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neodymium (Nd) YAG laser treatment
Study: 21956725
Drug: Clobazam 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 0.5 mg/kg/day
Study: 21956725
Drug: Clobazam 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 0.25 mg/kg/day
Study: 10335771
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors alone
Study: 2751276
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC administered 0.5 h before enoxacin
Study: 2751276
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC administered 2 h before enoxacin
Study: 2751276
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC administered 8 h before enoxacin
Study: 2751276
Drug: Maalox TC
Normalized name: Aluminum Hydroxide/Magnesium Hydroxide 225 MG/5 ML-200 MG/5 ML Oral Suspension [MAALOX TC]
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maalox TC administered 2 h after enoxacin
Study: 2751276
Drug: Ranitidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administered intravenously 2 h before enoxacin
Study: 31188779
Drug: Rational-Emotive Behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational-Emotive Behavior Therapy (REBT)
Study: 28858362
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (18 g containing 300 mg CGA in 200 mL hot water)
Study: 28858362
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (18 g containing 287 mg CGA in 200 mL hot water)
Study: 19375519
Drug: Oral mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral mesalamine 1 g twice daily
Study: 16391575
Drug: Calcium (1
Normalized name: hydroxyapatite 275 mg calcium (1,100 mg) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1 g) and Vitamin D3 (800 IU) supplementation once daily for 1 year
Study: 10842553
Drug: Daily iron/folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron/folate supplement (60 mg iron/0.25 mg folate per day)
Study: 10842553
Drug: Weekly iron/folate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron/folate supplement (120 mg iron/0.50 mg folate once a week)
Study: 8518219
Drug: MPA (medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPA (medroxyprogesterone acetate) 500 mg i.m. daily for 28 days, then 500 mg i.m. twice weekly for 5 months
Study: 8607407
Drug: Caffeine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.3 mg/kg)
Study: 29446548
Drug: 12-h combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h combined physical and psychological treatment programme
Study: 27530188
Drug: Ketoconazole 400
Normalized name: ketoconazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 400 mg once daily for 7 days, edoxaban on day 4
Study: 27530188
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg four times daily for 8 days, edoxaban on day 7
Study: 27530188
Drug: Cyclosporine 500
Normalized name: Cyclosporine 500 microgram/mL eye suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine 500 mg single dose with edoxaban
Study: 23286674
Drug: Education program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education program via surface mail providing information on influenza vaccine effectiveness and safety (EPG)
Study: 16336797
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (10 ml) applied at the end of breast resection plus closed suction drains
Study: 12827575
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural anesthesia with meperidine (TEA-M) (2 mg/kg in 10-12 mL) (n = 35)
Study: 21412218
Drug: Alagebrium treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alagebrium treatment
Study: 9177871
Drug: 0.75 microgram
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 microgram of 1‐alpha‐hydroxyvitamin D3 with calcium (150 mg/day)
Study: 7954417
Drug: Vorozole 1
Normalized name: vorozole
DrugBank: Vorozole (DB13767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole 1 mg
Study: 7954417
Drug: Vorozole 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole 2.5 mg
Study: 7954417
Drug: Vorozole 5
Normalized name: vorozole
DrugBank: Vorozole (DB13767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole 5 mg
Study: 7954417
Drug: Vorozole (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorozole (all doses)
Study: 3300966
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant endocrine therapy)
Study: 20929123
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine for nourishing yin and clearing heat therapy (CM therapy)
Study: 20929123
Drug: Standard Western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Western medical therapy
Study: 6341904
Drug: Sulphamethizole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphamethizole (1 g eight-hourly)
Study: 30605952
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBT-i)
Study: 30605952
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT-i with tapered hypnotic agents
Study: 17638699
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg bevirimat
Study: 15868998
Drug: Placebo (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (normal saline 2 ml just before induction)
Study: 8531545
Drug: Pyronaridine 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyronaridine 32 mg/kg, orally divided over 3 days
Study: 8531545
Drug: Chloroquine 25
Normalized name: chloroquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine 25 mg/kg, orally divided over 3 days
Study: 26798083
Drug: Injections in
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections in the abdomen
Study: 1857645
Drug: Injections in
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections in the thigh
Study: 1857645
Drug: Injections in
Normalized name: Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections in the arm
Study: 6418506
Drug: hypertonic salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: hypertonic salt and mannitol solution (415 mosmol/l)
Study: 6418506
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: isotonic saline mannitol solution with 105 mmol/l sodium, 93 mmol/l chloride, 10 mmol/l potassium and 22 mmol/l bicarbonate as well as 70 mmol/l mannitol (or 70 mmol/l polyethylene glycol)
Study: 23063624
Drug: Home-based functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based functional exercises (twice-weekly 60-minute sessions for 6 months)
Study: 12562649
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) and adjuvant chemotherapy (ACT) every 2 weeks with granulocyte-macrophage colony-stimulating factor (GM-CSF) support (arm B, 'dose-dense treatment')
Study: 12562649
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) and adjuvant chemotherapy (ACT) every 3 weeks (arm A, 'standard treatment')
Study: 12562649
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms received three courses of CEF followed by local therapy and three courses of CEF alternated with three courses of CMF.
Study: 12562649
Drug: Dose intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose intensity of chemotherapy in arm B
Study: 12562649
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of treatment in arm B
Study: 12562649
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of treatment in arm A
Study: 26675765
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation at 60 μg/d
Study: 17901735
Drug: silver‐sulfadiazine cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: silver‐sulfadiazine cream
Study: 12407041
Drug: 150 micro
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micro g desogestrel with testosterone pellets
Study: 12407041
Drug: 300 micro
Normalized name: Voglibose 300 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micro g desogestrel with testosterone pellets
Study: 12407041
Drug: 150 micro
Normalized name: Norgestrel 150 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 micro g and 300 micro g desogestrel with testosterone pellets
Study: 12042267
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral desogestrel with depot testosterone
Study: 18098237
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ramipril
Study: 17565489
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril
Study: 2806622
Drug: Medium B
Normalized name: CVS Medium Briefs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium B (2% UltroSer G)
Study: 17668979
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD; 20 mg twice a day)
Study: 2729930
Drug: Cefmetazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmetazole (2 g intravenously)
Study: 2729930
Drug: Cefmetazole with
Normalized name: Cefmetazole
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefmetazole with probenecid pretreatment (1 g orally)
Study: 2729930
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g intravenously)
Study: 31277120
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no eculizumab treatment)
Study: 9578182
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (400 ml)
Study: 15013031
Drug: Ritanserin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritanserin (10 mg p.o.)
Study: 28153353
Drug: Nebulised magnesium
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised magnesium sulphate (1ml of 15% magnesium sulphate + 1.5ml isotonic saline) with nebulised salbutamol (0.15mg/kg/dose)
Study: 28153353
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (0.15mg/kg/dose) and 2.5ml isotonic saline (Placebo group)
Study: 25279787
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose GQD (n=52)
Study: 25279787
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GQD (n=50)